282 related articles for article (PubMed ID: 32312269)
1. Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.
Keane S; Améen S; Lindlöf A; Ejeskär K
Cell Commun Signal; 2020 Apr; 18(1):65. PubMed ID: 32312269
[TBL] [Abstract][Full Text] [Related]
2. 11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma.
Siaw JT; Javanmardi N; Van den Eynden J; Lind DE; Fransson S; Martinez-Monleon A; Djos A; Sjöberg RM; Östensson M; Carén H; Trøen G; Beiske K; Berbegall AP; Noguera R; Lai WY; Kogner P; Palmer RH; Hallberg B; Martinsson T
Cell Rep; 2020 Sep; 32(12):108171. PubMed ID: 32966799
[TBL] [Abstract][Full Text] [Related]
3. DLG2 impairs dsDNA break repair and maintains genome integrity in neuroblastoma.
Keane S; de Weerd HA; Ejeskär K
DNA Repair (Amst); 2022 Apr; 112():103302. PubMed ID: 35217496
[TBL] [Abstract][Full Text] [Related]
4. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
5. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
6. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP
Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971
[TBL] [Abstract][Full Text] [Related]
7. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
[TBL] [Abstract][Full Text] [Related]
8. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.
Zhang X; Zhan S; Guan X; Zhang Y; Lu J; Yu Y; Jin Y; Yang Y; Chu P; Hong E; Yang H; Ren H; Geng D; Wang Y; Zhou P; Guo Y; Chang Y
Cancer Sci; 2023 Jul; 114(7):2860-2870. PubMed ID: 37094904
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets.
Coronado E; Yañez Y; Vidal E; Rubio L; Vera-Sempere F; Cañada-Martínez AJ; Panadero J; Cañete A; Ladenstein R; Castel V; Font de Mora J
Mol Oncol; 2021 Feb; 15(2):364-380. PubMed ID: 33252831
[TBL] [Abstract][Full Text] [Related]
10. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
[TBL] [Abstract][Full Text] [Related]
11. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
12. The loss of DLG2 isoform 7/8, but not isoform 2, is critical in advanced staged neuroblastoma.
Keane S; Martinsson T; Kogner P; Ejeskär K
Cancer Cell Int; 2021 Mar; 21(1):170. PubMed ID: 33726762
[TBL] [Abstract][Full Text] [Related]
13. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism.
Mandriota SJ; Valentijn LJ; Lesne L; Betts DR; Marino D; Boudal-Khoshbeen M; London WB; Rougemont AL; Attiyeh EF; Maris JM; Hogarty MD; Koster J; Molenaar JJ; Versteeg R; Ansari M; Gumy-Pause F
Oncotarget; 2015 Jul; 6(21):18558-76. PubMed ID: 26053094
[TBL] [Abstract][Full Text] [Related]
14. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
15. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma.
Spitz R; Hero B; Ernestus K; Berthold F
Clin Cancer Res; 2003 Jan; 9(1):52-8. PubMed ID: 12538451
[TBL] [Abstract][Full Text] [Related]
16.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
17. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
[TBL] [Abstract][Full Text] [Related]
18. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatics analysis of miRNAs in the neuroblastoma 11q-deleted region reveals a role of miR-548l in both 11q-deleted and MYCN amplified tumour cells.
Jurcevic S; Keane S; Borgmästars E; Lubovac-Pilav Z; Ejeskär K
Sci Rep; 2022 Nov; 12(1):19729. PubMed ID: 36396668
[TBL] [Abstract][Full Text] [Related]
20. Downregulated NORAD in neuroblastoma promotes cell proliferation via chromosomal instability and predicts poor prognosis.
Yu Y; Chen F; Jin Y; Yang Y; Wang S; Zhang J; Chen C; Zeng Q; Han W; Wang H; Guo Y; Ni X
Acta Biochim Pol; 2020 Dec; 67(4):595-603. PubMed ID: 33326736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]